PP405 (Suvomipic)

Early human Skin & Hair 2 sources

PP405 is an investigational topical small-molecule and peptide-like compound designed to activate dormant hair follicle stem cells. Research shows it works by inhibiting the mitochondrial pyruvate carrier (MPC), forcing a metabolic shift that stimulates hair follicles to re-enter the growth phase.

01Dosing reference

Amount

Investigational topical concentrations (e.g., 1% to 5% gel/solution)

Frequency

Once or twice daily

Cycle

Continuous daily use during clinical trials (e.g., 4-12 weeks)

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Mitochondrial Pyruvate Carrier (MPC) Inhibition

PP405 binds to and inhibits the MPC protein complex in dormant hair follicle stem cells.

Metabolic Reprogramming

By blocking pyruvate from entering the mitochondria, the cell shifts its metabolism from oxidative phosphorylation to glycolysis, increasing lactate production.

Stem Cell Activation

This specific metabolic shift acts as a trigger, waking up the dormant stem cells and forcing them to re-enter the anagen (growth) phase to produce new hair.

03Human evidence

PP405 demonstrated safety, tolerability, and initial signs of stimulating hair growth in early trials.

Phase 1 and Phase 2a clinical trials evaluating topical application in individuals with androgenetic alopecia.

Top-line results indicate an increase in hair density and reactivation of dormant follicles.

Short-term topical application in male and female pattern hair loss patients, though long-term efficacy remains under investigation.

04Preclinical evidence

Topical application rapidly induced the hair cycle and robust hair growth in animal models.

Studies in mice showed that inhibiting MPC in hair follicle stem cells robustly stimulated entry into the anagen phase.

Genetic deletion of MPC led to similar hair growth effects as pharmacological inhibition.

Validated the mechanism of action using genetic knockout mouse models, confirming that MPC inhibition is responsible for the stem cell activation.

05What is known vs. unknown

Reasonably established

PP405 is a topical treatment designed to reactivate dormant hair follicle stem cells.
It works by inhibiting the mitochondrial pyruvate carrier (MPC), altering cellular metabolism.
The metabolic shift towards glycolysis is a key trigger for hair follicle stem cell activation.
It is currently in Phase 2 clinical trials for androgenetic alopecia (pattern hair loss).

Unknowns & limits

Long-term safety and efficacy of continuous MPC inhibition in human scalps are not fully established.
It is unclear if PP405 can restore hair in areas with completely miniaturized or dead follicles, or only in recently dormant ones.
Potential for follicle exhaustion with prolonged use is a theoretical concern raised by some researchers.

06Safety & regulatory context

Regulatory statusPP405 is currently an investigational drug and is not FDA-approved. In early clinical trials (Phase 1 and 2a), it has been well-tolerated as a topical formulation with minimal systemic absorption. Potential side effects are primarily localized to the application site, such as mild scalp irritation. Because it alters cellular metabolism, long-term safety studies are necessary to ensure it does not cause unintended metabolic consequences or exhaust the stem cell pool over time.

07Compared with Minoxidil

PP405 (Suvomipic) vs. Minoxidil

Key difference

Minoxidil is a vasodilator that prolongs the anagen phase and increases blood flow, whereas PP405 directly targets stem cell metabolism to force dormant follicles into the growth phase.

When researchers discuss each

Minoxidil is discussed as the standard first-line topical treatment for hair loss, while PP405 is discussed as a novel, targeted regenerative approach for non-responders or as a potential combination therapy.

08Glossary

Mitochondrial Pyruvate Carrier (MPC)

A protein complex that transports pyruvate into the mitochondria for energy production; its inhibition alters cell metabolism.

Anagen Phase

The active growth phase of hair follicles.

Glycolysis

A metabolic pathway that breaks down glucose to produce energy, which is upregulated when MPC is inhibited.

09Knowledge check

Q1What is the primary mechanism of action of PP405?

Q2What metabolic shift occurs in hair follicle stem cells when treated with PP405?

Q3Which interpretation best matches the human evidence and limitations reported in the dossier for PP405?

Q4According to the dossier, how is PP405 most clearly different from minoxidil in mechanism and proposed research role?

Q5Which statement accurately reflects the safety and regulatory context of PP405 as described in the dossier?

10Sources

Journal Overview of Short Peptides for Hair Loss
ClinicalTrials.gov A Study to Evaluate the Safety, Tolerability, and Efficacy of PP405 in Subjects With Androgenetic Alopecia

More in Skin & Hair

See all

GHK-Cu

Skin & Hair

Human clinical

GHK-Cu is a naturally occurring copper complex first isolated from human plasma. Research shows it plays a significant role in promoting wound healing, stimulating collagen synthesis, and modulating gene expression to support tissue repair and anti-aging processes.

1-2 mg/day (SubQ) or 1-3% concentration (topical)

Acetyl Octapeptide-3 (SNAP-8)

Skin & Hair

Human clinical

SNAP-8 (Acetyl Octapeptide-3) is a synthetic octapeptide designed as an elongated, more potent version of the popular hexapeptide Argireline. It functions as a topical "Botox-like" peptide by modulating the SNARE complex to reduce the release of acetylcholine, thereby relaxing facial muscles and reducing the depth of expression wrinkles.

2% to 10% concentration in topical formulations

Melanotan II

Skin & Hair

Human clinical

Melanotan II is a synthetic analog of the alpha-melanocyte-stimulating hormone (α-MSH). It was originally developed to induce skin pigmentation (tanning) to protect against UV radiation, but research also demonstrated significant effects on sexual arousal and erectile function.

250-500 mcg per injection

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.